Physician profile
Mamerto M Lebita
NPI 1538198353
$3,892.76
in general payments reported to CMS, 2019-2025
27 companies · $571 in 2025
The $571 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $947 · 2021: $493 · 2022: $343 · 2023: $143 · 2024: $518 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $690.57 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $665.71 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $499.20 | 2019-2025 | |
| Astellas Pharma US INC | $243.85 | 2019-2021 | |
| Allergan, INC. | $207.98 | 2020 | |
| Amgen INC. | $185.40 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $174.15 | 2020-2022 | |
| Lilly USA, LLC | $157.95 | 2019-2021 | |
| Gilead Sciences, INC. | $125.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $124.29 | 2024 | Voquezna |
| Abbvie INC. | $110.05 | 2021-2023 | |
| Novo Nordisk INC | $101.48 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $99.52 | 2024-2025 | Xtampza, Belbuca |
| Janssen Pharmaceuticals, INC | $94.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $65.70 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.74 | 2022-2023 | Xifaxan |
| Shield Therapeutics INC | $54.54 | 2024-2025 | |
| Exact Sciences Corporation | $50.05 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $34.87 | 2020 | |
| Dexcom, INC. | $26.11 | 2025 | Dexcom G6 Transmitter |
| Dentsply Ih Ab | $25.57 | 2024 | Navina Rectal Catheter Set Regular |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.02 | 2020 | |
| Verona Pharma, INC. | $20.71 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $17.86 | 2025 | Zoryve |
| Inspire Medical Systems, INC. | $17.78 | 2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $11.36 | 2021 | |
| Amneal Pharmaceuticals LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamerto Lebita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.